JP2020536097A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020536097A5 JP2020536097A5 JP2020519138A JP2020519138A JP2020536097A5 JP 2020536097 A5 JP2020536097 A5 JP 2020536097A5 JP 2020519138 A JP2020519138 A JP 2020519138A JP 2020519138 A JP2020519138 A JP 2020519138A JP 2020536097 A5 JP2020536097 A5 JP 2020536097A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- binding fragment
- composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims description 95
- 102000036639 antigens Human genes 0.000 claims description 95
- 108091007433 antigens Proteins 0.000 claims description 95
- 239000012634 fragment Substances 0.000 claims description 95
- 238000000034 method Methods 0.000 claims description 58
- 238000005303 weighing Methods 0.000 claims description 46
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 36
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 claims description 31
- 206010018370 Glomerulonephritis membranoproliferative Diseases 0.000 claims description 23
- 238000012423 maintenance Methods 0.000 claims description 22
- 229940109239 creatinine Drugs 0.000 claims description 18
- 230000006698 induction Effects 0.000 claims description 16
- 201000001474 proteinuria Diseases 0.000 claims description 14
- 102000009027 Albumins Human genes 0.000 claims description 12
- 108010088751 Albumins Proteins 0.000 claims description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 12
- 229920001184 polypeptide Polymers 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 238000010253 intravenous injection Methods 0.000 claims description 10
- 208000016323 C3 glomerulonephritis Diseases 0.000 claims description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 8
- 208000022401 dense deposit disease Diseases 0.000 claims description 8
- 230000001404 mediated effect Effects 0.000 claims description 8
- 210000002966 serum Anatomy 0.000 claims description 8
- 102000004506 Blood Proteins Human genes 0.000 claims description 4
- 108010017384 Blood Proteins Proteins 0.000 claims description 4
- 208000029574 C3 glomerulopathy Diseases 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 4
- 238000001574 biopsy Methods 0.000 claims description 4
- 235000012000 cholesterol Nutrition 0.000 claims description 4
- 230000024924 glomerular filtration Effects 0.000 claims description 4
- 238000005534 hematocrit Methods 0.000 claims description 4
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 claims description 4
- 229960001025 iohexol Drugs 0.000 claims description 4
- HUOOMAOYXQFIDQ-UHFFFAOYSA-N isoginkgetin Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C(C=3C(=CC=C(C=3)C=3OC4=CC(O)=CC(O)=C4C(=O)C=3)OC)=C2O1 HUOOMAOYXQFIDQ-UHFFFAOYSA-N 0.000 claims description 4
- 230000003907 kidney function Effects 0.000 claims description 4
- 238000005259 measurement Methods 0.000 claims description 4
- 208000027134 non-immunoglobulin-mediated membranoproliferative glomerulonephritis Diseases 0.000 claims description 4
- 229910052700 potassium Inorganic materials 0.000 claims description 4
- 239000011591 potassium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 4
- 230000002485 urinary effect Effects 0.000 claims description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims description 2
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- 229960001230 asparagine Drugs 0.000 claims description 2
- 235000009582 asparagine Nutrition 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- 108010068617 neonatal Fc receptor Proteins 0.000 claims description 2
- 235000018102 proteins Nutrition 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 75
- 238000001802 infusion Methods 0.000 claims 6
- 238000001990 intravenous administration Methods 0.000 claims 6
- 102000001554 Hemoglobins Human genes 0.000 claims 1
- 108010054147 Hemoglobins Proteins 0.000 claims 1
- 201000008171 proliferative glomerulonephritis Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023089908A JP2023101717A (ja) | 2017-10-04 | 2023-05-31 | 膜性増殖性糸球体腎炎患者の処置のための抗ｃ５抗体の投薬量および投与 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762568060P | 2017-10-04 | 2017-10-04 | |
| US62/568,060 | 2017-10-04 | ||
| US201862652615P | 2018-04-04 | 2018-04-04 | |
| US62/652,615 | 2018-04-04 | ||
| PCT/US2018/053976 WO2019070714A1 (en) | 2017-10-04 | 2018-10-02 | ASSAY AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR THE TREATMENT OF PATIENTS WITH MEMBRANOPROLIFERATIVE GLOMERULONEPHRIPT |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023089908A Division JP2023101717A (ja) | 2017-10-04 | 2023-05-31 | 膜性増殖性糸球体腎炎患者の処置のための抗ｃ５抗体の投薬量および投与 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020536097A JP2020536097A (ja) | 2020-12-10 |
| JP2020536097A5 true JP2020536097A5 (enExample) | 2021-11-04 |
Family
ID=64051671
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020519138A Pending JP2020536097A (ja) | 2017-10-04 | 2018-10-02 | 膜性増殖性糸球体腎炎患者の処置のための抗ｃ５抗体の投薬量および投与 |
| JP2023089908A Pending JP2023101717A (ja) | 2017-10-04 | 2023-05-31 | 膜性増殖性糸球体腎炎患者の処置のための抗ｃ５抗体の投薬量および投与 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023089908A Pending JP2023101717A (ja) | 2017-10-04 | 2023-05-31 | 膜性増殖性糸球体腎炎患者の処置のための抗ｃ５抗体の投薬量および投与 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20200262897A1 (enExample) |
| EP (2) | EP3692064A1 (enExample) |
| JP (2) | JP2020536097A (enExample) |
| KR (1) | KR20200059279A (enExample) |
| CN (1) | CN111278857A (enExample) |
| AU (1) | AU2018345625A1 (enExample) |
| BR (1) | BR112020006692A2 (enExample) |
| CA (1) | CA3078362A1 (enExample) |
| CO (1) | CO2020004831A2 (enExample) |
| MX (1) | MX2020003619A (enExample) |
| WO (1) | WO2019070714A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| EP3340983B1 (en) | 2015-08-26 | 2023-10-04 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| EP3589287B1 (en) | 2017-03-01 | 2022-09-14 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for treatment of medical disorders |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| CN110603252A (zh) | 2017-03-01 | 2019-12-20 | 艾其林医药公司 | 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物 |
| EP3661493A4 (en) | 2017-08-02 | 2021-04-14 | Achillion Pharmaceuticals, Inc. | TREATMENT DIET FOR THE TREATMENT OF PAROXYSTIC NOCTURAL HEMOGLOBINURIA |
| WO2019227102A1 (en) * | 2018-05-25 | 2019-11-28 | Achillion Pharmaceuticals, Inc. | Complement alternative pathway-associated nephropathy biomarkers |
| US11814391B2 (en) | 2018-09-06 | 2023-11-14 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
| MX2021002640A (es) | 2018-09-06 | 2021-07-16 | Achillion Pharmaceuticals Inc | Formas morficas de los inhibidores del factor d del complemento. |
| EP3856164B1 (en) | 2018-09-25 | 2024-08-07 | Achillion Pharmaceuticals, Inc. | Morphic forms of complement factor d inhibitors |
| US12239645B2 (en) | 2018-12-17 | 2025-03-04 | Achillion Pharmaceuticals, Inc. | Targeted dosing for the treatment of complement mediated disorders |
| JP7635138B2 (ja) | 2019-03-22 | 2025-02-25 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 補体媒介性障害の治療のための医薬化合物 |
| JP2022542430A (ja) * | 2019-08-01 | 2022-10-03 | ヤンセン バイオテツク，インコーポレーテツド | Ｆｃｒｎ抗体およびその使用の方法 |
| CN116712390B (zh) * | 2023-08-04 | 2023-11-14 | 上海览屹医药科技有限公司 | 一种高浓度高稳定性的抗体制剂及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| RS64039B1 (sr) * | 2008-11-10 | 2023-04-28 | Alexion Pharma Inc | Metode i kompozicije za lečenje poremećaja povezanih sa komplementom |
| NZ631007A (en) * | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| US20180142010A1 (en) * | 2015-06-26 | 2018-05-24 | Alexion Pharmaceuticals, Inc. | Method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant |
| PE20240825A1 (es) * | 2016-06-17 | 2024-04-18 | Chugai Pharmaceutical Co Ltd | Anticuerpos anti-c5 y metodos de uso |
-
2018
- 2018-10-02 EP EP18796165.1A patent/EP3692064A1/en not_active Withdrawn
- 2018-10-02 JP JP2020519138A patent/JP2020536097A/ja active Pending
- 2018-10-02 CN CN201880065034.5A patent/CN111278857A/zh active Pending
- 2018-10-02 EP EP24174774.0A patent/EP4424324A3/en active Pending
- 2018-10-02 US US16/651,520 patent/US20200262897A1/en not_active Abandoned
- 2018-10-02 BR BR112020006692-3A patent/BR112020006692A2/pt not_active IP Right Cessation
- 2018-10-02 MX MX2020003619A patent/MX2020003619A/es unknown
- 2018-10-02 WO PCT/US2018/053976 patent/WO2019070714A1/en not_active Ceased
- 2018-10-02 CA CA3078362A patent/CA3078362A1/en not_active Abandoned
- 2018-10-02 AU AU2018345625A patent/AU2018345625A1/en not_active Abandoned
- 2018-10-02 KR KR1020207012177A patent/KR20200059279A/ko not_active Withdrawn
-
2020
- 2020-04-20 CO CONC2020/0004831A patent/CO2020004831A2/es unknown
-
2023
- 2023-02-28 US US18/115,226 patent/US20240025975A1/en active Pending
- 2023-05-31 JP JP2023089908A patent/JP2023101717A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020536097A5 (enExample) | ||
| JP7489978B2 (ja) | 抗ＦｃＲｎ抗体を用いたグレーブス眼症の治療方法 | |
| JP2022023051A (ja) | 瘻孔を伴うクローン病の治療用ベドリズマブ | |
| JP2009541374A5 (enExample) | ||
| US20210000949A1 (en) | Methods for treating or preventing asthma by administering an il-33 antagonist | |
| IL300376A (en) | Inflammatory cytokines and fatigue in subjects with complement-mediated disease | |
| JP2021524839A (ja) | 抗ｐｃｓｋ９抗体を含む製剤およびその使用 | |
| WO2017059813A1 (zh) | 抗乙肝表面抗原的抗体及其用途 | |
| KR20240151809A (ko) | Fcrn 길항제를 사용하여 근염을 치료하는 방법 | |
| JP7722991B2 (ja) | 抗ｆｃｒｎ抗体を用いた温熱自己免疫性溶血性貧血の治療方法 | |
| WO2024102732A1 (en) | Methods for the treatment of cardiovascular disease | |
| JP2018533588A (ja) | 治療パラダイム | |
| US20210230265A1 (en) | Methods for treating copd by administering an il-33 antagonist | |
| JPWO2019231983A5 (enExample) | ||
| JPWO2021247779A5 (enExample) | ||
| CN113993543B (zh) | 使用抗cd38抗体的组合疗法 | |
| TWI886758B (zh) | 抗pvrig/抗tigit雙特異性抗體在治療惡性腫瘤中的用途 | |
| JP2019505516A (ja) | インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法 | |
| CN120000779A (zh) | 抗il-5抗体治疗与嗜酸性粒细胞升高相关疾病的用途 | |
| WO2025072725A1 (en) | Methods for the treatment of cardiovascular disease | |
| CN117120092A (zh) | 用于治疗儿科重症肌无力的组合物和方法 | |
| WO2024112561A1 (en) | Methods for the treatment of myasthenia gravis | |
| JP2024517087A (ja) | 小児重症筋無力症を治療するための組成物及び方法 | |
| WO2025186787A1 (en) | Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia | |
| EP4334351A1 (en) | Treatment for systemic lupus erythematosus using anti-baffr antibodies |